|Publication Type||Journal Article|
|Year of Publication||2006|
|Authors||Pikman, Y, Lee, BH, Mercher, T, McDowell, E, Ebert, BL, Gozo, M, Cuker, A, Wernig, G, Moore, S, Galinsky, I, DeAngelo, DJ, Clark, JJ, Lee, SJ, Golub, TR, Wadleigh, M, Gilliland, DG, Levine, RL|
The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid metaplasia (MF). Subsequent analysis has shown that constitutive activation of the JAK-STAT signal transduction pathway is an important pathogenetic event in these patients, and that enzymatic inhibition of JAK2V617F may be of therapeutic benefit in this context. However, a significant proportion of patients with ET or MF are JAK2V617F-negative. We hypothesized that activation of the JAK-STAT pathway might also occur as a consequence of activating mutations in certain hematopoietic-specific cytokine receptors, including the erythropoietin receptor (EPOR), the thrombopoietin receptor (MPL), or the granulocyte-colony stimulating factor receptor (GCSFR).